Diagnosis and Complication Risk Assessment of Pancreatic Diabetes within Normal Value Ranges of Leuc
This method use rapid or Automatic test device for procalcitonin blood levels.
This patent can use for daily complication risk Assessment of all diabetic patients and save lifes, suffering from the diabetic complications at all around the world. it is more important method than Hemoglobin A1c. Because all diabetic complications can monitorizing using one marker (procalcitonin) in 24 hours period. New technology of insulin pump system or traditional diabetes mellitus therapy need this invention for proper diabetic complication (retinopathy, nephropathy,neuropathy) treatment
License Agreement
Inventor: Soylemez, Mehmet Ali
Priority Number: EP2626704B1
IPC Current: G01N003368
Title: DIAGNOSIS OF PANCREATIC DIABETES IN PATIENTS WITH NORMAL BLOOD LEUCOCYTE COUNTS USING PROCALCITONIN | DIAGNOSE VON BAUCHSPEICHELDRÜSEN DIABETES BEI PATIENTEN MIT NORMALEN BLUT LEUKOZYTENZAHLEN UNTER VERWENDUNG VON PROCALCITONIN | DIAGNOSTIC DU DIABÈTE PAN
Usefulness: DIAGNOSIS OF PANCREATIC DIABETES IN PATIENTS WITH NORMAL BLOOD LEUCOCYTE COUNTS USING PROCALCITONIN | DIAGNOSE VON BAUCHSPEICHELDRÜSEN DIABETES BEI PATIENTEN MIT NORMALEN BLUT LEUKOZYTENZAHLEN UNTER VERWENDUNG VON PROCALCITONIN | DIAGNOSTIC DU DIABÈTE PANCRÉATIQUE CHEZ LES PATIENTS AVEC LES VALEURS NORMALES DE LEUCOCYTES SANGUINS EN UTILISANT LA PROCALCITONINE
Summary: The method is useful for performing in vitro diagnosis of pancreatic diabetes mellitus and/or pancreatic diabetes mellitus complications chosen from diabetic microangiopathy, retinopathy, nephropathy, neuropathy, retinopathy, macroangiopathy and diabetic foot syndrome and/or risk stratification of pancreatic diabetes mellitus, for assessing degree of severity and for assessing the course of pancreatic diabetes mellitus, preferably type II diabetes mellitus, and its sequelae and concomitant illnesses, preferably endothelial dysfunction, hyperlipoproteinemia, hypertensive dysregulation of the cardiovascular system, diabetic microangiopathy, retinopathy, nephropathy, renal insufficiency, neuropathy, macroangiopathy, diabetic foot syndrome and cardiovascular complications (all claimed).
Novelty: Performing in vitro diagnosis of pancreatic diabetes mellitus and/or pancreatic diabetes mellitus complications e.g. diabetic microangiopathy, involves determining procalcitonin in patient within normal value ranges of leucocytes
Disease Diagnostic/Treatment
Other Disease
EP20120154587
Price Indication: Negotiable
Status: Patent Application
Patent Area: EPO designated contracting states
Turkiye
